Core Viewpoint - Health Catalyst has appointed Ben Albert as the new CEO, effective February 12, 2026, to enhance operational efficiency, clinical quality, and consumer experience in healthcare [1] Leadership Changes - Ben Albert, previously President and COO, has taken over from Dan Burton, who will remain with the company as a strategic advisor [1] - The Board of Directors will be reduced to five members by the 2026 Annual Meeting, with several directors stepping down [1] Strategic Focus - Albert aims to streamline operations and align resources with high-return priorities to improve financial performance [1] - The company plans to leverage its technology and expertise to help clients manage costs and improve clinical quality [1] Board Composition - Dawn Smith and Duncan Gallagher have stepped down from the Board, with John Kane set to leave on April 1, 2026 [1] - Matt Arens has been named Chair of the Nominating and Corporate Governance Committee, while Julie Larson-Green continues as Chair of the Compensation Committee [1] Company Background - Health Catalyst is a leading provider of data and analytics technology and services, serving over 1,100 organizations globally [2] - The company focuses on transforming complex healthcare data into actionable insights, contributing to measurable improvements in clinical, financial, and operational outcomes [2]

Core Viewpoint - Health Catalyst (HCAT) is experiencing significant selling pressure, with a 20.4% decline over the past four weeks, but is now positioned for a potential trend reversal as it enters oversold territory, supported by analyst expectations of better earnings than previously predicted [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to identify oversold conditions, with a reading below 30 typically indicating that a stock is oversold [2]. - HCAT's current RSI reading is 28.93, suggesting that the heavy selling may be exhausting itself, indicating a potential bounce back towards equilibrium in supply and demand [5]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that HCAT's earnings estimates for the current year have increased by 128.1% over the last 30 days, which typically correlates with price appreciation in the near term [7]. - HCAT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8].

Core Viewpoint - Health Catalyst (HCAT) has experienced a significant downtrend, with a 21.4% decline over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to analysts' positive earnings outlook [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to identify oversold conditions, with a reading below 30 indicating that a stock may be oversold [2]. - HCAT's current RSI reading is 28.93, indicating that the heavy selling pressure may be exhausting, which could lead to a price rebound [5]. - RSI helps investors identify potential entry points for stocks that have fallen below their fair value due to excessive selling [3]. Group 2: Fundamental Indicators - Analysts covering HCAT have raised earnings estimates for the current year, resulting in a 128.1% increase in the consensus EPS estimate over the last 30 days, which typically correlates with price appreciation [7]. - HCAT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating strong potential for a near-term turnaround [8].

Core Viewpoint - Health Catalyst (HCAT) has shown a downtrend recently, losing 7.5% over the past two weeks, but a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottom in the stock price, suggesting that selling pressure may be exhausting [2][5]. - A hammer pattern forms when there is a small candle body with a long lower wick, indicating that the stock opened lower, made a new low, but closed near or above the opening price, reflecting some buying interest [4][5]. - This pattern is significant when it occurs at the bottom of a downtrend, signaling that bears may be losing control [5]. Fundamental Analysis - There has been a positive trend in earnings estimate revisions for HCAT, which is a bullish indicator suggesting potential price appreciation [7]. - The consensus EPS estimate for the current year has increased by 125% over the last 30 days, indicating strong agreement among analysts about improved earnings potential [8]. - HCAT currently holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Financial Results - Health Catalyst, Inc. published preliminary unaudited estimated financial results for 2025 on January 12, 2026[4] - The financial results are subject to change upon completion of the company's accounting and annual audit procedures[4] - Additional information and disclosures will be required for a complete understanding of the company's financial condition as of December 31, 2025[4]

Company Overview - Phreesia, Inc. (NYSE:PHR) is a healthcare technology company focused on enhancing patient intake and engagement while streamlining administrative processes in healthcare settings [1][5] - The company operates in a competitive landscape alongside peers such as Health Catalyst, Veracyte, Accolade, Castle Biosciences, and Personalis, each providing unique solutions in the healthcare technology sector [1] Financial Performance - Phreesia's Return on Invested Capital (ROIC) is -12.98%, indicating that the company is not generating returns above its cost of capital [2][5] - The company's Weighted Average Cost of Capital (WACC) is 6.71%, leading to a ROIC to WACC ratio of -1.93, which suggests inefficient capital utilization [2][5] Peer Comparison - Health Catalyst has a ROIC of -16.99% and a WACC of 6.12%, resulting in a ROIC to WACC ratio of -2.78, indicating even less efficient capital utilization than Phreesia [3] - Accolade and Personalis also exhibit negative ROIC to WACC ratios of -2.91 and -3.19, respectively, reflecting similar challenges in generating returns above their cost of capital [3] - Castle Biosciences has a ROIC of -4.44% and a WACC of 8.60%, resulting in a ROIC to WACC ratio of -0.52, which, while still negative, is closer to breaking even compared to other peers [4] Industry Challenges - Overall, Phreesia and its peers face significant challenges in generating sufficient returns to cover their cost of capital, which raises concerns for investors [4]

Core Viewpoint - Health Catalyst, Inc. has appointed Matt Arens, CEO and Founder of First Light Asset Management, to its board of directors, effective December 1, 2025, which is expected to enhance the company's strategic focus and shareholder value creation efforts [1][3]. Company Overview - Health Catalyst is a leading provider of data and analytics technology and services aimed at improving healthcare outcomes, with over 1,100 organizations relying on its offerings [6]. - The company operates a cloud-based technology ecosystem called Health Catalyst Ignite™, which provides AI-enabled data and analytics solutions [6]. Shareholder Information - First Light Asset Management is the largest shareholder of Health Catalyst, owning approximately 19% of the company's outstanding shares, which equates to about 13.9 million shares [2]. - Matt Arens has been a shareholder since Health Catalyst's IPO in 2019 [2]. Board Composition - The addition of Matt Arens to the board is seen as a significant move due to his extensive experience in capital markets and healthcare investments [3]. - Matthew Kolb, a current director since 2023, will not seek re-election at the 2026 annual meeting, marking a change in board composition [5]. Strategic Insights - Matt Arens expressed that the market is not fully recognizing the value within Health Catalyst, citing a low EBITDA multiple and high free cash flow generation potential as indicators of significant appreciation opportunities for the company's shares [5]. - The firm has a proven track record of delivering billions of dollars in measurable results, reinforcing its commitment to data-informed healthcare improvement [6].

Core Insights - Health Catalyst, Inc. (NASDAQ:HCAT) is actively participating in several investor conferences to showcase its data and analytics solutions and discuss its strategies and performance [1][6] Conference Participation - The company will attend the Stephens Annual Investment Conference in Nashville on November 19, 2025, featuring a fireside chat [2] - Health Catalyst will also be present at the Canaccord Genuity MedTech, Diagnostics and Digital Health and Services Forum in New York on November 20, 2025, offering one-on-one meetings [2] - Additional participation includes the 8th Annual Evercore Healthcare Conference in Miami on December 2, 2025, and Citi's 2025 Global Healthcare Conference in Miami on December 3, 2025 [2] Technology and Operations - Health Catalyst's operations are centered around its cloud-based technology, Health Catalyst Ignite, which utilizes AI-enabled data and analytics to enhance clinical, financial, and operational outcomes [3][6] - The platform supports over 1,100 organizations globally, delivering billions in measurable results by transforming complex data into actionable insights [3][6] Financial Performance - In its recent financial report, Health Catalyst achieved earnings per share of $0.06, surpassing the estimated $0.05 [4][6] - The company reported a revenue of $76.32 million, exceeding the estimated $73.97 million [4][6] - Health Catalyst demonstrated efficiency with an asset turnover ratio of 0.51 [4][6] - For the most recent quarter, the company reported a cost of revenue of $38.51 million and operating expenses of $55.33 million, resulting in a gross profit of $37.82 million [5]

Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

Core Insights - Health Catalyst (HCAT) reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of $0.05 per share, but down from $0.07 per share a year ago [1][2] - The company achieved a revenue of $76.32 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.66%, and slightly down from $76.35 million year-over-year [3] Earnings Performance - The earnings surprise for the quarter was +20.00%, following a previous surprise of +33.33% when earnings were $0.04 per share against an expectation of $0.03 [2] - Over the last four quarters, Health Catalyst has exceeded consensus EPS estimates two times and revenue estimates three times [2][3] Stock Performance - Health Catalyst shares have declined approximately 60% since the beginning of the year, contrasting with the S&P 500's gain of 14.4% [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [7] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.10 on revenues of $74.59 million, and for the current fiscal year, it is $0.19 on revenues of $309.8 million [8] - The Medical Info Systems industry, to which Health Catalyst belongs, is ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [9]